M. Walters

发表

Discovery of Potent and Selective PI3Kγ Inhibitors.

N. Walker, U. Schindler, J. Powers, 2020, Journal of medicinal chemistry.

Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels

T. Schall, B. Zabel, J. Jaén, 2014, Immunology.

CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease.

James J. Campbell, C. Weston, D. Adams, 2018, American journal of physiology. Gastrointestinal and liver physiology.

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.

T. Schall, T. Sullivan, J. Jaén, 2013, Metabolism: clinical and experimental.

Fluticasone, but not salmeterol, reduces cigarette smoke-induced production of interleukin-8 in human airway smooth muscle.

K. Chung, J. Mitchell, Malcolm W Johnson, 2008, Pulmonary pharmacology & therapeutics.

Heme oxygenase is expressed in human pulmonary artery smooth muscle where carbon monoxide has an anti-proliferative role.

T. Evans, J. Mitchell, R. Motterlini, 2003, European journal of pharmacology.

Cigarette smoke induces IL-8, but inhibits eotaxin and RANTES release from airway smooth muscle

K. Chung, J. Mitchell, M. John, 2005, Respiratory research.

Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice

T. Schall, N. Miyasaka, T. Kanai, 2014, Arthritis Research & Therapy.

Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ).

N. Walker, U. Schindler, J. Powers, 2021, Journal of medicinal chemistry.

CC Chemokine Receptor 2 Promotes 1 Recruitment of Myeloid Cells Associated with 2 Insulin Resistance in Non-Alcoholic Fatty Liver 3 Disease 4

James J. Campbell, C. Weston, D. Adams, 2018 .

CCR9 Antagonists in the Treatment of Ulcerative Colitis

James J. Campbell, T. Schall, T. Sullivan, 2015, Mediators of inflammation.

CCR 9 Antagonists in the Treatment of Ulcerative Colitis

James J. Campbell, T. Schall, T. Sullivan, 2015 .

Carbon monoxide inhibits endothelin-1 release by human pulmonary artery smooth muscle cells.

J. Mitchell, M. Walters, S. Stanford, 2004, European journal of pharmacology.

A Systemically-Administered Small Molecule Antagonist of CCR9 Acts as a Tissue-Selective Inhibitor of Lymphocyte Trafficking

James J. Campbell, T. Schall, N. Tubo, 2012, PloS one.

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

J. Powers, L. Seitz, Lixia Jin, 2019, Investigational New Drugs.

Pyruvate aldolases in chiral carbon–carbon bond formation

E. Toone, M. Walters, 2007, Nature Protocols.

Preparation of 2‐(1‐phenyl‐1H‐pyrazol‐5‐yl)benzenesulfonamides from polylithiated C(α),N‐phenylhydrazones and methyl 2‐(aminosulfonyl)benzoate

D. VanDerveer, M. Embree, N. Camper, 2005 .

The preparation of benzoisothiazolo[1,2-b][1,2]isoquinolin-11-one-1,1-dioxides from dilithiated ortho-toluic acids and lithiated methyl 2-(aminosulfonyl)benzoate

W. Pennington, M. Krawiec, M. Walters, 2004 .

The preparation of 3‐substituted 1,2‐benzisothiazole‐1,1‐dioxides from the condensation‐cyclization of dilithiated β‐ketoesters with methyl 2‐(aminosulfonyl)benzoate or 1,2‐benzisothiazol‐3(2H)‐one‐1,1‐dioxide

D. VanDerveer, N. Camper, W. Pennington, 2006 .

The Preparation of 5-Aryl-5-methyl-4,5-dihydroisoxazoles from Dilithiated C(α), O -Oximes and Select Acetyl Ketones

M. Walters, C. F. Beam, S. Dunn, 2003 .

Molecular Basis for Cyclooxygenase Inhibition by the Non-steroidal Anti-inflammatory Drug Naproxen*

L. Marnett, J. Oates, J. Harp, 2010, The Journal of Biological Chemistry.

Preparation of 4,5‐Dihydronaphth[2,1‐c]isoxazoles from Dilithiated 2‐Tetralone Oxime and Select Esters

Maria D. Malatanos, M. Walters, J. Rhett, 2008 .

The preparation of 3-substituted 1,2-benzisothiazole 1,1-dioxides from lithiated intermediates or grignard reagents and methyl 2-(aminosulfonyl)benzoate

M. Walters, Laela M. Hajiaghamohseni, Sara Lioi, 2004 .

Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

Yu Wang, T. Schall, J. Jaén, 2010, Journal of Pharmacology and Experimental Therapeutics.

CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens.

T. Schall, T. Sullivan, J. Jaén, 2013, Immunology letters.

Discovery of Potent and Selective 7-Azaindole Isoindolinone-Based PI3Kγ Inhibitors.

N. Walker, U. Schindler, J. Powers, 2020, ACS medicinal chemistry letters.

EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY

Tina N. Davis, Forrest M Kievit, Atique U. Ahmed, 2013 .

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats

M. Merchant, L. Recht, H. Kohrt, 2014, British Journal of Cancer.

Discovery of AB680 - A Potent and Selective Inhibitor of CD73.

N. Walker, N. Sträter, Lijuan Fu, 2020, Journal of medicinal chemistry.

Cigarette Smoke Activates Human Monocytes by an Oxidant-AP-1 Signaling Pathway: Implications for Steroid Resistance

I. Adcock, J. Mitchell, M. Paul-Clark, 2005, Molecular Pharmacology.

Antagonism of CXCR7 attenuates chronic hypoxia–induced pulmonary hypertension

K. Young, M. Penfold, C. Suguihara, 2012, Pediatric Research.

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity

A. Becker, J. Powers, A. Udyavar, 2022, Molecular cancer therapeutics.

The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives.

Andrew S. Felts, Anna L. Blobaum, L. Marnett, 2009, Bioorganic & medicinal chemistry letters.

Cigarette smoke inhibits macrophage sensing of Gram‐negative bacteria and lipopolysaccharide: relative roles of nicotine and oxidant stress

M. Paul-Clark, S. Sriskandan, S. McMaster, 2008, British journal of pharmacology.

AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.

L. Horvath, J. Powderly, L. Seitz, 2019, Journal of Clinical Oncology.

Discovery and Characterization of a Potent and Selective Inhibitor for Human Phosphoinositide‐3‐kinase γ

J. Powers, Lixia Jin, Xiaoning Zhao, 2020, The FASEB Journal.

Characterization and crystal structure of Escherichia coli KDPGal aldolase.

E. Toone, C. Fierke, J. Naismith, 2008, Bioorganic & medicinal chemistry.

Directed evolution of a pyruvate aldolase to recognize a long chain acyl substrate.

E. Toone, Manoj Cheriyan, C. Fierke, 2011, Bioorganic & medicinal chemistry.

Abstract A162: AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression

F. Soriano, U. Schindler, J. Powers, 2019, Maintenance of Immune Balance: Effects of Targeted and Immune Therapies.

Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control

F. Soriano, U. Schindler, J. Powers, 2018, Clinical Research (Excluding Clinical Trials).

Abstract 4572: Characterization of the potent and selective A2aR antagonist AB928 for the treatment of cancer

A. Becker, J. Jaén, J. Powers, 2017 .

509 Potent and selective inhibition Of AXL receptor tyrosine kinase for the treatment of cancer

J. Powers, A. Udyavar, S. Cho, 2020, Journal for ImmunoTherapy of Cancer.

46P AB521, a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor, for the treatment of renal cell carcinoma

F. Soriano, A. Mailyan, L. Seitz, 2022, Annals of Oncology.

Differences in CXCR7 protein expression on rat versus mouse and human splenic marginal zone B cells.

T. Schall, J. Jaén, M. Penfold, 2013, Immunology letters.

Abstract 1756: Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy

U. Schindler, Lixia Jin, Ada Chen, 2018, Immunology.

Abstract 710: CD73 inhibitors (CD73i) reverse the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors (ICI)

A. Becker, U. Schindler, J. Powers, 2018, Immunology.

Abstract 4980: Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers

A. Udyavar, A. Anderson, D. Direnzo, 2019, Immunology.

AB680, a potent and selective CD73 small molecule inhibitor, reverses the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors

A. Becker, U. Schindler, J. Powers, 2018 .

258 AB308 is an anti-TIGIT antibody that enhances immune activation and anti-tumor immunity alone and in combination with other I-O therapeutic agents

F. Soriano, Xiaoning Zhao, Ada Chen, 2021, Journal for ImmunoTherapy of Cancer.